Physician profile
Uma Menon
NPI 1629289319
$9,873.29
in general payments reported to CMS, 2019-2025
15 companies · $351 in 2025
The $351 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $1,768 · 2021: $259 · 2022: $1,391 · 2023: $4,874 · 2024: $98.25 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,523 · Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,523.00 |
| Food and Beverage | $799.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $5,661.14 | 2019-2024 | |
| Neuropace, INC. | $1,318.63 | 2020 | |
| Abbvie INC. | $1,238.11 | 2022 | |
| Sk Life Science, INC. | $344.13 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $333.76 | 2019-2020 | |
| Greenwich Biosciences, INC. | $297.82 | 2019 | |
| Eisai INC. | $187.49 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $124.06 | 2025 | |
| Amgen INC. | $121.84 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $104.20 | 2023 | |
| Lilly USA, LLC | $77.94 | 2023 | Emgality, Reyvow |
| Livanova USA, INC. | $17.63 | 2019 | |
| Neurelis, INC. | $17.47 | 2020 | |
| Lundbeck LLC | $16.11 | 2019 | |
| Portola Pharmaceuticals, LLC | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.